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Abstract: The CD19 marker is expressed on the surface of normal and malignant immature 
or mature B-cells. On the other hand, immunotherapy involving T-cells is a promising 
modality of treatment for many neoplastic diseases including leukemias and lymphomas. 
The CD19/CD3-bispecific T-cell-engaging (BiTE®) monoclonal antibody blinatumomab can 
transiently engage cytotoxic T-cells to CD19+ target B-cells inducing serial perforin-mediated 
lysis. In the first clinical trial, blinatumomab showed efficacy in non-Hodgkin’s lymphomas, 
but the most important trials have been conducted in relapsed/refractory (R/R) acute lympho-
blastic leukemia (ALL) and in ALL with minimal residual disease. Encouraging reports on the 
activity of blinatumomab in R/R Philadelphia chromosome-negative B-cell precursor ALL 
led to its approval by the US Food and Drug Administration on December 3, 2014 after an 
accelerated review process. This review focuses on the profile of blinatumomab and its activity 
in R/R ALL.
Keywords: acute lymphoblastic leukemia, relapsed/refractory, BiTE® monoclonal antibodies, 
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Introduction
Immunotherapy is a promising modality of treatment for many neoplastic diseases 
including leukemias and lymphomas.1 Among the several strategies used, the 
engagement of cytotoxic T-cells to the neoplastic cells irrespective of their T-cell 
receptor specificity has led to highly effective lysis of these cells. Two therapeutic 
modalities have been demonstrated to be useful for the treatment of B-cell leukemias 
and lymphomas. The first uses the ectopic expression of a CD19-specific chimeric 
antigen receptor (CAR) construct in transfected autologous T-cells of patients (CAR 
T-cells).2–4 The second modality includes the bispecific CD19/CD3 T-cell-engaging 
monoclonal antibody (MoAb), blinatumomab, which can transiently engage any 
cytotoxic T-cell to CD19+ target B-cells.5–8 Both CAR T-cells and blinatumomab have 
been successfully used in patients with B-cell precursor (BCP) acute lymphoblastic 
leukemia (ALL), non-Hodgkin’s lymphomas, and chronic lymphocytic leukemia.
With regard to BCP ALL, the CD19 marker has been used as a target for 
immunotherapy.2 Several generations and types of CD19 CAR T-cells have been 
developed showing a high efficiency in the lysis of CD19-positive blast cells.3,4 In turn, 
blinatumomab has demonstrated promising activity and a favorable safety profile in 
relapsed/refractory (R/R) ALL and in ALL with minimal residual disease (MRD), and 
is currently being evaluated in first-line therapy in adults with BCP ALL.5–8
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Here, we review the pharmacologic profile, the clinical 
results, and the safety and tolerability of blinatumomab for 
treating R/R BCP ALL.
Pharmacologic profile 
of blinatumomab
Mechanism of action of blinatumomab
A bispecific T-cell-engaging (BiTE®) antibody is made up 
of the variable antigen-binding domains of two antibodies 
connected by a non-immunogenic peptide acting as a linker.9 
This construct allows to engage the T-cells to the target 
neoplastic cell, subsequently activating the T-cells and 
causing the perforin-mediated death of the malignant cell.10 
Blinatumomab (derived from “B lineage-specific antitumor 
mouse monoclonal antibody”) is the most clinically advanced 
BiTE® antibody, and includes an anti-CD3 arm to engage 
CD3-expressing T-cells and an anti-CD19 arm to bind to 
lymphoblasts expressing the CD19 marker. More than 90% 
of cases of BCP ALL express CD19 in more than 20% of 
malignant cells, the intensity of expression being sufficient 
to make this therapy suitable in ALL.11 Due to its single-
chain structure, blinatumomab is approximately one-third 
the size of the typical MoAb. The non-immunogenic linker 
protein that binds the anti-CD19 and anti-CD3 antibodies 
enables a great degree of rotational flexibility which allows 
for close proximity of malignant CD19-positive B-cells to 
CD3-positive T-cells, favoring direct lysis. The activity of 
blinatumomab and other BiTE® MoAbs does not depend on 
the specificity of the T-cell receptor and does not require 
major histocompatibility complex class 1 and/or peptide anti-
gens, thereby allowing nonspecific recruitment of polyclonal 
T-cells and avoiding the downregulation of major histocom-
patibility complex class molecules, a known mechanism of 
tumor resistance.5
Blinatumomab engages the CD19-positive ALL blast cell 
to the CD3-positive T-cell, forming an immune synapsis that 
leads to upregulation of the T-cell activation markers CD25, 
CD69, CD2, interferon-γ, tumor necrosis factor-α, interleukin 
(IL)-2, IL-6, and IL-10. These activated T-cells (especially the 
CD8-positive subset) induce perforin-mediated cytotoxicity 
via granzyme entry into the ALL blast, which subsequently 
leads to caspase activation and apoptosis of the blast cell. 
In addition to T-cell activation, blinatumomab causes marked 
T-cell proliferation. Furthermore, blinatumomab-activated 
T-cells are capable of serial killing of the CD19-positive 
target cells. One possible hypothesis for this serial lysis lies in 
the preferential binding of CD19 as compared to CD3 which 
potentially allows the T-cells to be released from the target 
cells enabling them to bind to additional target B-cells. The 
T-cell proliferation and the serial killing of CD19-positive 
B-cells induced by blinatumomab explain why this MoAb 
is also effective in patients with a limited number of T-cells 
due to prior intensive therapy or early after hematopoietic 
stem cell transplantation (HSCT).12–16
Pharmacokinetic data
Several different blinatumomab administration schedules 
have been studied including short intravenous (IV) admin- 
istration as well as 28-day continuous IV (CIV) adm-
inistration.
The decision to give blinatumomab as a CIV infusion 
for 28 days was based on the evidence described in the first 
studies in which the majority of tumor responses were seen 
during the first 4 weeks of treatment. Subsequent studies of 
blinatumomab have therefore employed a CIV duration of 
4 weeks with a 2-week break between cycles, and the main 
pharmacokinetic (PK) studies are derived according to this 
administration.
The mean (± standard deviation) steady-state serum con-
centration of blinatumomab is 731±163 pg/mL and is reached 
within 1 day and is not modified in subsequent cycles. The 
volume of distribution is 1.61±0.74 L/m2, with a mean clear-
ance of 22.3±5 L/day/m2 and a half-life of 1.25±0.63 hours. 
Systemic clearance is not affected by creatinine clearance, 
age, sex, weight, or body surface area.
The optimal dose of blinatumomab has been investigated 
in several studies. In vivo activity has been observed at doses 
as low as 5 µg/m2/day, but several studies have shown that 
CIV doses of greater than or equal to 15 µg/m2/day are needed 
for suppressing the ALL B-cells and that these doses lead to 
serum blinatumomab concentrations of 0.6 ng/mL, which are 
maintained throughout the infusion period.12–17
Limited PK data are available in pediatric patients, but 
serum concentrations similar to those achieved in adults with 
attainment of steady-state concentrations within 48 hours 
were established in Phase I trials.18
Pharmacodynamic data
Data from the Phase II trial of blinatumomab in patients 
with MRD-positive ALL have shown that within the first 
few hours after the administration of blinatumomab, T-cell 
counts fall in all patients and recover to baseline levels in the 
subsequent days.12 A subsequent expansion of T-cells then 
occurs, and on average, their number more than doubles 
that of baseline within 2–3 weeks under continued infusion 
of blinatumomab.12 The initial fall in T-cells is attributed 
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to a redistribution phenomenon thought to be caused by an 
increased adhesion of T-cells to the endothelium. Addition-
ally, B-cells rapidly decrease and fall below the limit of 
detection in less than 2 days, remaining undetectable for the 
duration of the blinatumomab infusion.12,19,20 The low dose 
of blinatumomab needed for response (compared with con-
ventional MoAb) is likely related to the high lytic potential 
of cytotoxic T-cells. These T-cells can rapidly adopt a serial 
lysis mode and can proliferate at the site of their activation. 
Activation of T-cells equally stimulates proliferation of 
CD4+ and CD8+ cytotoxic cells as long as target cells are 
available, but no signs of uncontrolled T-cell activation or 
T-cell anergy have been observed.12,19 Granzyme B is detect-
able in serum during the first 6–48 hours of blinatumomab 
treatment. A transient release of cytokines (especially IL-6, 
IL-10, and interferon-γ) is observed in most patients, the 
cytokine peak concentrations being dose dependent.12,19 
Production of inflammatory cytokines can be problematic, 
and patients must be hospitalized for several days, particu-
larly at the start of the first course (when the tumor burden 
is highest and a dose step at day 8 is used in the current 
schedules) to monitor possible infusion reactions or other 
toxicities (eg, neurological). No autoimmune responses have 
been reported to date in published trials.
Efforts have been made to find predictive markers of the 
efficacy of blinatumomab. In an analysis of 31 patients with 
R/R ALL treated with blinatumomab at a single center, the 
T-regulatory (T
reg
) lymphocytes of the T-cell compartment 
were monitored by flow cytometry, and a logistic regression 
model was developed to delineate responders vs nonre-
sponders to blinatumomab. A high percentage of T
reg
 cells 
(over 12.5%) and high serum lactate dehydrogenase level 
were found to be independent predictors of lack of response 
to blinatumomab.21 Upfront removal of T
reg
 cells might 
restore proliferation of T-cells, and thus may be a strategy 
to convert R/R ALL blinatumomab nonresponder patients 
to responders.
Safety profile of blinatumomab
The most significant toxicities noted in the studies performed 
in R/R ALL (Table 1) and in MRD-positive ALL using the 
CIV dose of 15 µg/m2/day for 4 weeks with 2 weeks off 
between cycles were central nervous system (CNS) events 
and the cytokine release syndrome (CRS) (Table 2).22–27 
The most common adverse CNS events included enceph-
alopathy, aphasia, tremor, and disorientation, being revers-
ible in most cases but leading to early discontinuation of 
the drug in others. While not entirely comprehended, the 
cause of blinatumomab-related CNS toxicity is thought to 
be the adherence of activated T-cells to the endothelium. The 
activated T-cells then cross the blood–brain barrier (BBB) 
and enter the CNS, where they bind to the CD19-positive 
B-cells, which could possibly cause cytokine release and 
disruption of the BBB. This T-cell-mediated inflammation 
of the CNS is also seen with CAR T-cells.3,4 To prevent neu-
rological toxicity by blinatumomab, patients with the history 
or the presence of clinically relevant neurological pathology 
or active leukemia in CNS are excluded from treatment. 
Grade 3 neurological events are managed with temporary 
interruption of blinatumomab and dexamethasone treat-
ment. If these events are resolved, blinatumomab can be 
reintroduced starting with the lowest dose (5 µg/m2/day). 
For seizures, appropriate anticonvulsant treatment must be 
given on blinatumomab preinitiation. On the development 
of grade 4 neurological events, permanent discontinuation 
of blinatumomab is mandatory.28
The CRS is thought to occur due to rapid lysis of tumor 
cells by T-lymphocytes during the first infusion. The release 
of pro-inflammatory cytokines is more pronounced during 
the beginning of the first cycle of treatment. In most patients, 
CRS symptoms are mild and flu-like, with fever and myalgia. 
In more severe cases, a severe inflammatory syndrome 
is associated with vascular leak, hypotension, pulmonary 
edema, coagulopathy, and multiorgan system failure.29 Base-
line disease burden is associated with risk of CRS, and pre-
phase dexamethasone (10 mg/m2 up to 5 days) with or without 
cyclophosphamide (200 mg/m2 up to 3 days) is required 
for patients with more than 50% blasts or a peripheral blast 
count over 15×109/L. This pre-phase dexamethasone does 
not significantly impact the complete response (CR) rate. 
The reduction in the dose of blinatumomab to 5 µg/m2/day 
(or 9 µg/day) in the first week of the first cycle also prevents 
the development of CRS.28,29
Leukopenia with neutropenia, B-cell lymphocytopenia, 
and hypogammaglobulinemia can frequently be seen in 
patients treated with blinatumomab. Grade 3 neutropenia 
and febrile neutropenia were observed in 25% and 16% of 
patients included in the Phase II international trial in R/R 
ALL, respectively.25 An increased risk of infection may 
occur, although it is difficult to determine whether this is 
related to the effects of the treatment with blinatumomab 
(immune dysfunction, B-cell lymphocytopenia, and neutro-
penia) or to the underlying active ALL. In the aforementioned 
trial, deaths due to sepsis or infection considered to possibly 
be related to blinatumomab occurred in three patients, none 
of whom was in remission. The B-cell lymphocytopenia 





and hypogammaglobulinemia are persistent during the 
blinatumomab therapy, and IV immunoglobulin replacement 
can be considered in patients with severely decreased serum 
immunoglobulin levels. Preliminary data from the first pedi-
atric Phase I/II study suggest substantial similarities among 
the toxicity profiles described in adults.18
Clinical studies in R/R ALL patients
R/R ALL in adults
Despite the improvements in the results of the therapy in most 
adult ALL patients, relapse is the most frequent cause of thera-
peutic failure, and occurs in a half of the patients, being more 
frequent with increasing age. Advanced genomic techniques 
investigated the clonal diversity and evolution in acute leukemia. 
Studies of pediatric ALL demonstrated that in individual patients, 
there are multiple genetic subclones of leukemia-initiating cells, 
with a complex clonal architecture.30 Separate studies also 
investigating pediatric ALL determined that the clonal basis of 
relapse was variable and complex, with relapse often evolving 
from a clone ancestral to the predominant de novo leukemia 
clone.31 The results of the conventional rescue chemotherapy are 
poor, and only a small fraction of patients can achieve prolonged 
remission after alloHSCT. New therapeutic options are clearly 
required to try to solve this unmet medical need.
Table 1 Development program of blinatumomab in adults and children with R/R acute lymphoblastic leukemia
R/R Phase II GMALL 
trial
R/R Phase II international 
confirmatory trial
R/R pediatric Phase II 
trial
Patients enrolled 36 189 39
Dose of blinatumomab Varied by cohort First cycle: 9 µg/m2/day in week 1 
and 28 µg/m2/day thereafter
First cycle: 5 µg/m2/day 
for 7 days, then 15 µg/m2/day
5 µg/m2/day in week 1 and 
15 µg/m2/day thereafter in 
the extension phase
Subsequent cycles: 
28 µg/m2/day ×4 weeks
Subsequent cycles: 
15 µg/m2/day
Previous alloHSCT 15 (42%) 64 (34%) 25 (64%)
1st salvage: 6
$2nd salvage: 19
No prior alloHSCT 21 (58%) 125 (66%) 14 (36%)
Primary refractory 3 (8%) 29 (15%)
1st salvage 11 (31%) 55 (29%)
$2nd salvage 7 (19%) 41 (22%)
CR/CRh 25 (69%) 81 (43%) 12 (31%)*
RFS, median (months) 7.6 5.9 5.6
OS, median (months) 9.8 6.1 4.3
Note: *Two additional patients had blast-free hypoplastic/aplastic bone marrow.
Abbreviations: R/R, relapsed/refractory; GMALL, German Multicenter Adult Acute Lymphoblastic Leukemia Group; alloHSCT, allogeneic hematopoietic stem cell 
transplantation; CR, complete response; CRh, CR with incomplete hematologic recovery; RFS, relapse-free survival; OS, overall survival.
Table 2 Main toxicities observed in clinical trials in R/R acute lymphoblastic leukemia
Trial (reference) Blinatumomab schedule Most common 
adverse events




R/R Phase II GMALL trial 
(n=36)22






5 µg/m2/day in week 1 and 
15 µg/m2/day thereafter in the 
extension phase
R/R Phase II international 
confirmatory trial (n=189)25
First cycle: 9 µg/m2/day in 








28 µg/m2/day ×4 weeks
R/R pediatric Phase II trial 
(n=39)27
First cycle: 5 µg/m2/day 
for 7 days, then 15 µg/m2/day
Pyrexia, anemia, 
nausea, headache
Anemia, pyrexia, increased AST 




Increased AST and ALT
Abbreviations: R/R, relapsed/refractory; GMALL, German Multicenter Adult Acute Lymphoblastic Leukemia Group; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase.
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The first trial of blinatumomab in adults with R/R ALL 
was an open-label, multicenter, exploratory Phase II study 
performed by the German Multicenter Adult Acute Lym-
phoblastic Leukemia Group.24 R/R ALL was defined as ALL 
with .5% blasts in bone marrow (BM), and Philadelphia 
chromosome (Ph)-positive ALL if ineligible for tyrosine 
kinase inhibitors treatment, .3 months after alloHSCT 
or .6 months after autologous HSCT. The study included 
a dose-finding phase with three cohorts of patients followed 
by an extension phase with the schedule with the best safety 
profile. The primary endpoints were CR and CRh (CR with 
incomplete hematologic recovery, defined as #5% blasts in 
the BM, no evidence of circulating blasts or extramedullary 
disease, and partial recovery of peripheral blood counts 
[at least platelets .50,000/µL, hemoglobin .7 g/dL, and 
absolute neutrophil count .500/µL]) within two cycles of 
treatment. Two cycles of blinatumomab were scheduled, fol-
lowed by three additional consolidation cycles or alloHSCT 
in CR/CRh patients. Thirty-six patients were included (three 
primary refractory, 16 after first relapse and two after $2 
relapses, 15 in relapse after HSCT, two Ph-positive ALL, 
and four t(4;11)-positive ALL). The best safety profile was 
observed in the cohort including 5 µg/m2/day in week 1 
and 15 µg/m2/day thereafter and was selected for the 
extension phase. CR/CRh was attained in 25/36 patients 
(69%), with a CR rate of 42% (15/36) attained after the 
first cycle of blinatumomab in 18 out of 25 patients. MRD 
negativity (,10-4) across all cycles was achieved in 88% of 
responders (22/25). In the last update, at a median follow-up 
of 28.9 months, the median of relapse-free survival (RFS) 
was 8.8 months, and the median overall survival (OS) 
was 9.8 months (14.9 months after censoring of HSCT). 
Regarding safety, CRS requiring treatment discontinuation 
or interruption of blinatumomab occurred in three patients, 
neurological events requiring interruption of the treatment 
were observed in six patients (all restarted blinatumomab 
at a dose of 5 µg/m2, although two patients had recurring 
events and permanently stopped therapy), and one patient 
developed a fatal fungal encephalitis.
The results of a global Phase II study in R/R adult ALL 
patients with the following inclusion criteria have recently 
been published:25 Ph-negative ALL with primary resis-
tance to frontline therapy, early relapse (duration of first 
CR ,12 months), and second or later relapses. More than 
10% blasts in BM were required to include the patients in 
the trial. Treatment consisted of an induction phase including 
one to two cycles of blinatumomab (9 µg/m2/day in week 1 
and 28 µg/m2/day thereafter, as established in the previous 
Phase II dose-finding study) followed by a consolidation 
period with one to three cycles of blinatumomab. The 
primary endpoint was CR/CRh within the first two cycles. 
Out of the 189 patients treated, 81 (43%) achieved CR/CRh 
within the first two cycles (CR, 33% [63/189]; CRh, 10% 
[18/189]), with 79% (64/81) of the responders achieving 
CR/CRh in cycle 1. The CR/CRh rates were similar in the 
ALL subgroups, including elderly patients (11/25; 44%) and 
patients with prior alloHSCT (29/64; 45%). AlloHSCT was 
performed in 32 (40%) out of the 81 patients with CR/CRh. 
At a median follow-up of 8.9 months, the median RFS 
was 5.9 months. The median OS was 6.1 months (median 
follow-up 9.8 months), without differences after censor-
ing the follow-up at alloHSCT. The OS was significantly 
better for patients achieving CR/CRh after two treatment 
cycles (median of 9.9 months vs 2.7 months). Sixty out of 
73 patients (82%) who achieved CR/CRh within the first 
two cycles achieved MRD negativity (59 in cycle 1). The 
most frequent non-neurologic grade $3 adverse events 
(AEs) found in .5% of patients were febrile neutropenia 
(25%), neutropenia (16%), anemia (14%), thrombocytope-
nia (8%), and infections (pneumonia in 9%, sepsis in 6%). 
Three patients (2%) had grade 3 CRS (no grade 4 or 5 CRS 
events were registered). Grade $3 neurologic events were 
observed in 24 (13%) patients (grade 4 in four patients, 
with no cases of grade 5), and occurred in cycle 1 in 87% of 
cases. Grade 5 AE occurred in 28 (15%) patients, none of 
whom were in documented CR, and deaths were considered 
unrelated to blinatumomab.
A Phase II single-arm, multicenter trial aimed to evaluate 
the efficacy of blinatumomab in adults with R/R Ph-positive 
ALL (clinicaltrials.gov NCT02000427) is currently being 
conducted, and the accrual of the 41 patients has been com-
pleted. Adults ($18 years) with R/R Ph-positive ALL who 
were resistant or intolerant to at least one second-generation 
tyrosine kinase inhibitor (dasatinib, nilotinib, bosutinib, 
ponatinib) were eligible. An induction phase with two 
cycles of blinatumomab followed by up to three consolida-
tion cycles for subjects who achieved CR/CRh within two 
induction cycles was scheduled. The primary endpoint was 
the CR/CRh rate within two cycles of treatment.
An international Phase III, randomized, multicenter, open-
label study aimed to investigate the efficacy of blinatumomab 
vs standard of care (SOC) chemotherapy in adults with R/R 
Ph-negative BCP ALL (clinicaltrials.gov NCT02013167) 
is now underway. Adult patients ($18 years) in untreated 
first relapse with a first remission duration ,12 months or 
in untreated second or greater relapse or relapsed at any 





time after alloHSCT are eligible. A 2:1 randomization of 
blinatumomab vs SOC chemotherapy is planned. The bli-
natumomab arm includes two induction cycles followed 
by up to three consolidation cycles and by blinatumomab 
maintenance. AlloHSCT is allowed to be performed at any 
time in patients in CR/CRh after two cycles of blinatumomab 
or after SOC chemotherapy. No cross-over between arms is 
allowed. The primary endpoint is OS. Four hundred patients 
are expected to be recruited.
R/R ALL in children
The first results of a Phase I/II study of blinatumomab in pedi-
atric patients with R/R BCP ALL were presented in the 2014 
Meeting of the American Society of Hematology (ASH).18 
A total of 70 patients (Phase I/II and Phase II studies) were 
included. Eligible patients were less than 18 years old with 
BCP ALL in second or later BM relapse, in any BM relapse 
after alloHSCT, or refractory to induction or reinduction 
therapy. Escalating dose levels of 5 µg/m2/day, 15 µg/m2/day, 
and 30 µg/m2/day and stepwise dosing of 5–15 µg/m2/day 
or 15–30 µg/m2/day were evaluated. The primary endpoint 
of the Phase I part of the study was to determine the maxi-
mum tolerated dose (MTD). Forty-one patients received a 
total of 73 cycles (median 1 cycle). Eight (20%) patients 
had refractory disease, and seven (17%) had experienced 
at least two BM relapses. Twenty-six (63%) patients had 
relapsed following HSCT. The MTD was established at 
15 µg/m2/day. To decrease the risk of CRS, a stepwise dose 
of 5–15 µg/m2/day was recommended for the Phase II part of 
the study (5 µg/m2/day for 7 days, then 15 µg/m2/day in the 
first cycle and 15 µg/m2/day in subsequent cycles). Across 
all dosing levels, 13 (32%) patients had CR, with ten (77%) 
achieving MRD negativity. Of these 13 patients, nine (69%) 
underwent alloHSCT. The median RFS was 8.3 months, and 
the median OS was 5.7 months with a median follow-up of 
12.4 months.
The primary endpoint for the Phase II part of the study 
was the CR/CRh rate. The results from the first 39 patients 
recruited were presented separately in the same ASH 
Meeting.27 Sixteen (41%) patients had one, and 16 (41%) 
had two or more prior salvage therapies; seven (18%) 
were either primary refractory or had refractory relapse. 
Twenty-five (64%) patients had received prior alloHSCT. 
Out of the 39 patients, 34 (87%) had relapsed within 6 months 
prior to study entry. During the first two treatment cycles, 
12 patients (31%) achieved CR, mainly during the first cycle. 
Two additional patients (5%) had blast-free hypoplastic or 
aplastic BM. Among the patients with CR in the first two 
cycles, five (42%) had complete MRD response. The median 
RFS was 5.6 months, and the median OS was 4.3 months at 
6 months of follow-up. Six (50%) out of the 12 patients with 
CR proceeded to alloHSCT.
Causes of failure of treatment 
with blinatumomab
Despite the promising results of treatment with blinatu-
momab, a significant number of patients do not respond or 
experience relapse. The causes of this resistance are not well 
known. In a significant proportion of patients, the leukemic 
blasts do not express CD19 on their surface, suggesting CD19 
internalization or, most probably, selection of CD19-negative 
subclones being present at low level at relapse. On the other 
hand, a high percentage of T
reg
 cells (that regulate the T-cell 
proliferation) and high serum lactate dehydrogenase levels 
(probably reflecting the leukemic burden) were independent 
predictors of lack of response to blinatumomab.21 Some of the 
relapses after blinatumomab are extramedullary, especially 
in CNS, suggesting an insufficient activity of blinatumomab 
in sanctuary sites.
Current and future development 
of blinatumomab for ALL
From the results of the Phase II trials of blinatumomab in 
R/R ALL, blinatumomab (Blincyto®) was approved by the 
US Food and Drug Administration on December 3, 2014 
following an accelerated review process, for patients with 
R/R Ph-negative ALL. Blinatumomab will be submitted to 
the European Medicines Agency during 2015.
The results of the ongoing Phase II trial in R/R patients 
with Ph-positive ALL are awaited with interest. The pre-
liminary results of a global Phase II trial of blinatumomab 
in patients with MRD-positive BCP ALL have recently 
been reported,28 showing reversion to an MRD-negative 
status in 80% of patients after two cycles of blinatumomab. 
In addition, two Phase III studies, one designed by the 
National Cancer Institute/Children’s Oncology Group and 
another by the International Berlin-Frankfurt-Münster, 
are under development for pediatric patients. On the 
other hand, an ongoing Phase III study of combination 
chemotherapy with or without blinatumomab in patients 
with newly diagnosed Ph-negative B-lineage ALL is being 
conducted in the US by the Eastern Cooperative Oncology 
Group. In summary, blinatumomab has shown promising 
efficacy with a favorable safety profile in patients with 
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R/R or MRD-positive BCP ALL and is currently being 
investigated in earlier phases of the disease, confirming 
the importance of immunotherapy as a therapeutic strategy 
for patients with ALL.32
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